製品番号: HY-131611

6-Azuridine

(別名: 6-Azauridine; )

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

6-Azuridine (6-Azauridine) is an orally active purine nucleoside analogue. 6-Azuridine activates autophagic flux, induces Apoptosis that depends on AMPK and p53. 6-Azuridine exhibit both antitumor and antiviral activities.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.83%
CAS 番号: 54-25-1
分子式: C₈H₁₁N₃O₆
分子量:245.19

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

6-Azuridine 構造式

CAS 番号: 54-25-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

AMPK アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
BHK-21	EC₅₀	26 μM Compound: 6-azauridine	Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 18760610]
BHK-21	CC₅₀	>100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	26 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	>100 μM Compound: NM 299	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	CC₅₀	>100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method	[PMID: 25913116]
BHK-21	EC₅₀	46 μM Compound: NM 299	Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	[PMID: 25913116]
BHK-21	EC₅₀	>100 μM Compound: NM299	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	26 μM Compound: NM299	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	CC₅₀	>100 μM Compound: 6-Azauridine	Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29028528]
MT4	CC₅₀	0.2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT method Cytotoxicity against human MT4 cells after 96 hrs by MTT method	[PMID: 18054491]
MT4	CC₅₀	2 μM Compound: 6-azauridine	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	2 μM Compound: 6-Azauridine	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	2 μM Compound: NM299	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
Vero	IC₅₀	>100 μM Compound: 6-azauridine	In vitro cytotoxicity in vero cells. In vitro cytotoxicity in vero cells.	[PMID: 11689085]
Vero	CC₅₀	20 μM Compound: 6-azauridine	Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	20 μM Compound: 6-Azauridine	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	>20 μM Compound: 6-Azauridine	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>20 μM Compound: 6-Azauridine	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>20 μM Compound: 6-Azauridine	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.2 μM Compound: 6-Azauridine	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.2 μM Compound: 6-AUdr	Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	≥12.5 μM Compound: 6-AUdr	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	≥12.5 μM Compound: 6-aza-uridine	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 299	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	0.9 μM Compound: NM 299	Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.4 μM Compound: 6-Azauridine	Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining	[PMID: 26119992]
Vero	CC₅₀	57.26 μM Compound: 6-azauridine	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 26698879]
Vero	EC₅₀	4.48 μM Compound: 6-azauridine	Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay	[PMID: 26698879]
Vero	CC₅₀	>10 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay	[PMID: 29277307]
Vero 76	EC₅₀	>20 μM Compound: 6-azauridine	Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	>20 μM Compound: 6-azauridine	Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	1.2 μM Compound: 6-azauridine	Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	>20 μM Compound: NM 299	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>20 μM Compound: NM 299	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	1.2 μM Compound: 6-aza-uridine	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining	[PMID: 22513121]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays	[PMID: 25014745]
Vero 76	CC₅₀	≥12.5 μM Compound: Aza	Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method	[PMID: 25014745]
Vero 76	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	10 μM Compound: NM 299	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	12 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	20 μM Compound: NM299	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: NM299	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: NM299	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.2 μM Compound: NM299	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	≥12.5 μM Compound: Aza	Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	CC₅₀	>12.5 μM Compound: 6-AU	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	1.2 μM Compound: 6-AU	Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay	[PMID: 27161176]
Vero 76	CC₅₀	16 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	EC₅₀	40 μM Compound: 6-Azauridine	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay	[PMID: 29028528]

体外実験

6-Azuridine shows antiviral activity against COVID-19 in ACE2 human cells, with EC₅₀ of 48 μM^[2].
6-Azuridine (5 μM, up to 8 h) increases adenosine 5′-triphosphate levels and decreases uracil, cytosine nucleotides in L5178Y mouse lymphoma cells^[3].
6-Azuridine (5-20 μM, 24 h) induces autophagy-mediated cell death in various human cancer cells (H460 and H1299) via a p53- and AMPK-dependent pathway^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

6-Azuridine (150 mg/kg, i.p., daily, 10-13 days) shows antiviral activity in swine infected with transmissible gastroenteritis virus^[5].
6-Azuridine (30 mg/kg/day, p.o., drinking water, 39-41 days) shows antitumor effect against plasma cell tumors (X-5563 and X-5647) in mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 54-25-1
性状 Solid
分子量 245.19
分子式 C₈H₁₁N₃O₆
Color White to off-white
SMILES

O=C(N1)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)N=CC1=O
別名

6-Azauridine;
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

ACS Omega

Infectious cDNA Clone of Chikungunya Virus 181/25 for Antiviral Assay Development. [Abstract]

2025 Dec 8;10(50):62145-62156. PMID: 41476561

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (101.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0785 mL

20.3923 mL

40.7847 mL

5 mM

0.8157 mL

4.0785 mL

8.1569 mL

10 mM

0.4078 mL

2.0392 mL

4.0785 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]

[2]. Yallappa G N, et al. Design and synthesis of pyrazole derivatives for in vitro screening to protect angiotensin-converting enzyme 2 human cells against COVID-19. Current Medicine Research and Practice, 2021, 11(5): 206-210.

[3]. Janeway CM, et al. Effects of 6-azauridine on nucleotides, orotic acid, and orotidine in L5178Y mouse lymphoma cells in vitro. Cancer Res. 1977 Dec;37(12):4382-8. [Content Brief]

[4]. Cha YE, et al. 6-Azauridine Induces Autophagy-Mediated Cell Death via a p53- and AMPK-Dependent Pathway. Int J Mol Sci. 2021 Mar 14;22(6):2947. [Content Brief]

[5]. Steffenhagen KA, et al. Evaluation of 6-azauridine and 5-iododeoxyuridine in the treatment of experimental viral infections. J Infect Dis. 1976 Jun;133(6):603-12. [Content Brief]

[6]. Conn HO, et al. Effect of 6-azauridine on plasma cell tumors of mice: correlation of antitumor effect with inhibition of orotic acid metabolism. Cancer Res. 1967 Apr;27(4):618-25. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0785 mL	20.3923 mL	40.7847 mL	101.9617 mL
	5 mM	0.8157 mL	4.0785 mL	8.1569 mL	20.3923 mL
	10 mM	0.4078 mL	2.0392 mL	4.0785 mL	10.1962 mL
	15 mM	0.2719 mL	1.3595 mL	2.7190 mL	6.7974 mL
	20 mM	0.2039 mL	1.0196 mL	2.0392 mL	5.0981 mL
	25 mM	0.1631 mL	0.8157 mL	1.6314 mL	4.0785 mL
	30 mM	0.1359 mL	0.6797 mL	1.3595 mL	3.3987 mL
	40 mM	0.1020 mL	0.5098 mL	1.0196 mL	2.5490 mL
	50 mM	0.0816 mL	0.4078 mL	0.8157 mL	2.0392 mL
	60 mM	0.0680 mL	0.3399 mL	0.6797 mL	1.6994 mL
	80 mM	0.0510 mL	0.2549 mL	0.5098 mL	1.2745 mL
	100 mM	0.0408 mL	0.2039 mL	0.4078 mL	1.0196 mL

Keywords

6-Azuridine

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

6-Azuridine

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Human Metabolite Library

Pain-Related Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 6-Azuridine

AMPK アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

6-Azuridine 関連分類

HY-131611 関連分類